-+ 0.00%
-+ 0.00%
-+ 0.00%
Goldman Sachs: Maintaining CSPC Group's (01093) “Buy” Rating Target Price Raised to HK$12.83
Share
Listen to the news

The Zhitong Finance App learned that Goldman Sachs released a research report saying that the third quarter results of CSPC Group (01093) were in line with expectations. Despite the weak performance of the API business, the proprietary drug business remained steady, with a year-on-year increase of 10%, mainly due to the strong performance of product lines related to the central nervous system (CNS). Among them, retail sales of the Group's core products “EnbiPu” and “Mingfule” continued to expand, driving related businesses to increase sharply by 32% year over year; however, the performance of the Group's anti-tumor product portfolio is still under pressure, and the release of materials will take time, and it has not yet become a new driving force for growth. Goldman Sachs maintained the “buy” rating of CSPC and raised the target price from HK$12.56 to HK$12.83.

The report points out that despite positive momentum in the proprietary drug business in the second and third quarters, management is cautiously optimistic about future growth and only expects positive growth in sales of finished pharmaceuticals in 2027. In the central nervous system sector, “Enbip” is expected to continue to support sales growth because its price remains unchanged after being included in the health insurance catalogue; “Mingfule” will offset the impact by expanding sales volume after the medical insurance price is reduced by about 9.4%. Management expects a number of new drugs to become important growth engines in 2027, including albumin-conjugated paclitaxel, GLP-1 drugs, and EGFR ADC drug SYS6010, which is expected to drive the oncology business back to a growth trajectory after continued pressure in 2026.

The report also mentioned the layout of CSPC Group's new technology platforms, including AI-assisted drug development, in vivo CAR-T therapy, mRNA vaccines, siRNA, and long-lasting release systems. Management said that the CD19-targeted in-vivo CAR-T therapy “SYS6055 injection” showed encouraging efficacy in the initial dose group, and the group plans to further expand it to the fields of autoimmune diseases and refractory solid tumors.

In terms of mRNA therapeutic vaccines, the company is promoting a research and development project targeting human papillomavirus (HPV). Management indicated that the project has shown early efficacy signals in cervical precancerous lesions and HPV-related solid tumors; in addition, SYS6077, a shared antigen cancer vaccine designed for common antigens related to colorectal cancer (CRC), is expected to begin phase I clinical trials in China in the fourth quarter of 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending